精华制药(002349) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 408,730,383.60, representing a 22.19% increase compared to CNY 334,493,742.71 in the same period last year[3] - Net profit attributable to shareholders was CNY 66,855,252.60, up 17.96% from CNY 56,677,913.02 year-on-year[3] - The net profit after deducting non-recurring gains and losses was CNY 62,208,068.96, reflecting a 10.17% increase from CNY 56,467,371.36 in the previous year[3] - The company reported a significant increase of 1000.00% in non-current assets due within one year, amounting to CNY 1,270,499.99, primarily due to interest from equity disposal[6] - Other income increased by 76.68% to CNY 4,199,465.59, driven by contributions from subsidiaries[6] - Total operating revenue for the current period reached ¥408,730,383.60, an increase from ¥334,493,742.71 in the previous period, representing a growth of approximately 22.2%[24] - Net profit for the current period was ¥74,853,545.20, compared to ¥62,561,935.39 in the previous period, reflecting a growth of approximately 19.0%[27] - The total comprehensive income attributable to the parent company's owners was 66,855,252.60, an increase from 56,677,913.02 in the previous period, representing a growth of approximately 17.4%[31] - Basic and diluted earnings per share were both 0.0821, compared to 0.0696 in the previous period, reflecting an increase of about 18.1%[31] Cash Flow - The net cash flow from operating activities decreased by 27.23% to CNY 49,036,733.84, down from CNY 67,386,448.72 in the same period last year[3] - Cash inflow from operating activities totaled 397,627,479.43, compared to 345,167,492.09 in the previous period, marking an increase of about 15.2%[35] - Cash outflow from operating activities was 348,590,745.59, up from 277,781,043.37 in the previous period, which is an increase of approximately 25.5%[35] - Cash flow from investment activities surged by 1069.23% to ¥152,000,000.00, driven by increased purchases of financial products by subsidiaries[9] - Net cash flow from investing activities was -35,780,083.95, a decline from 3,480,655.07 in the previous period, indicating a significant decrease[35] - Cash inflow from investing activities was 132,045,365.89, compared to 40,343,210.67 in the previous period, representing an increase of about 227%[35] - Cash outflow from financing activities totaled 69,737,246.56, compared to 59,346,535.09 in the previous period, reflecting an increase of approximately 17.5%[38] - The ending cash and cash equivalents balance was 587,566,629.96, down from 600,739,319.32 in the previous period, indicating a decrease of about 2.0%[38] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,186,456,433.06, a slight decrease of 0.36% from CNY 3,198,096,241.82 at the end of the previous year[3] - Total liabilities decreased to ¥540,606,283.81 from ¥628,539,798.06, a reduction of approximately 14.0%[23] - Shareholders' equity attributable to the parent company increased by 3.03% to CNY 2,303,677,278.16 from CNY 2,235,838,542.50 at the end of the previous year[3] - The company's equity attributable to shareholders increased to ¥2,303,677,278.16 from ¥2,235,838,542.50, showing a growth of about 3.0%[23] Expenses and Impairments - Total operating costs amounted to ¥317,954,488.35, up from ¥275,205,754.61, indicating an increase of about 15.6%[24] - Research and development expenses for the current period were ¥14,784,119.29, slightly up from ¥14,562,216.19, indicating a growth of approximately 1.5%[27] - Credit impairment losses rose by 164.42% to -¥3,105,271.67, primarily due to increased provisions for bad debts[9] - Asset impairment losses increased by 137.64% to -¥5,064,706.23, mainly due to significant inventory write-downs from a subsidiary[9] - The company reported a significant decrease in employee compensation payable, which fell to ¥43,712,493.98 from ¥54,541,707.20, a decline of about 19.8%[23] Taxation - The company recorded a 49.53% increase in taxes payable, totaling CNY 32,123,152.35, attributed to higher VAT and corporate income tax obligations[6] Shareholder Information - The total number of common shareholders at the end of the reporting period was 190,260[9] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 35.20% of the shares, totaling 286,592,160 shares[13]